Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: ohama h. Cancer Med. 2023 Jan;12(1):325-334. doi: 10.1002/cam4.4854. Epub 2022 Jun 3. Cancer Med. 2023. PMID: 35666040 Free PMC article.
The preventive effect of the impaired liver function for antiemetic therapy against chemotherapy-induced nausea and vomiting in hepatocellular carcinoma patients.
Nishikawa T, Asai A, Okamoto N, Yasuoka H, Nakamura K, Yokohama K, Ohama H, Tsuchimoto Y, Fukunishi S, Tsuda Y, Yamamoto K, Higuchi K. Nishikawa T, et al. Among authors: ohama h. J Clin Biochem Nutr. 2017 Nov;61(3):222-227. doi: 10.3164/jcbn.17-57. Epub 2017 Oct 19. J Clin Biochem Nutr. 2017. PMID: 29203965 Free PMC article.
Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y. Tada T, et al. Among authors: ohama h. Liver Int. 2020 Apr;40(4):968-976. doi: 10.1111/liv.14405. Epub 2020 Mar 1. Liver Int. 2020. PMID: 32064740
Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
Hiraoka A, Kumada T, Tada T, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Toyoda H, Ohama H, Tsutsui A, Itokawa N, Hayama K, Arai T, Imai M, Nakamura S, Michitaka K, Hiasa Y, Kudo M; Real-Life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group. Hiraoka A, et al. Among authors: ohama h. Oncology. 2020;98(5):295-302. doi: 10.1159/000506293. Epub 2020 Feb 25. Oncology. 2020. PMID: 32097925
132 results